gin had ranged from 11 to 20 Gy. All of these patients were examined using MET-PET scanning and some also underwent 201 Tl-SPECT scanning. The mean period between stereotactic radiosurgery and PET scanning was 12.1 months. After stereotactic radiosurgery within 3 weeks after PET scanning, in 11 patients a pathological diagnosis was made based on biopsy or resection. In another 10 patients in whom no pathological examination was undertaken the definitive diagnosis was based on their subsequent clinical course and MR imaging results after a long-term follow up of more than 5 months. Eight patients underwent MET-PET scanning before treatment and were diagnosed surgically ( Table 2) .
Twenty healthy volunteers (10 men and 10 women), ranging in age from 22 to 70 years (mean 46.9 years), were included as controls and underwent MET-PET scanning. Informed consent from these volunteers was a prerequisite for participation in the study. Female volunteers of childbearing age were not included in the study.
Neuroimaging Procedures
Positron emission tomography was performed using a scanner (HEADTOM IV; Shimadzu, Kyoto, Japan) with a spatial resolution of 4.5 mm (full width at half maximum) and a slice thickness of 6.5 mm (14 slices). Patients were placed in the scanner so that slices parallel to the orbitomeatal line could be obtained. After a transmission scan was obtained, a static scan of 10 minutes was performed 20 minutes after injection of 370 MBq of MET and within 30 seconds after a 4-hour fasting period. The PET images were reconstructed using measured attenuation correction. The portion of the tumor with the highest MET accumulation was selected as the ROI, and several circular ROIs with a diameter of 5 mm were located over the gray matter in the contralateral frontal lobe. If no abnormality could be detected, a circular ROI of the same size was located over the area corresponding to the abnormality demonstrated on MR imaging. The T/N was defined as the mean counts of radioisotope per pixel in the lesion or tumor ROI divided by the mean counts per pixel in several normal gray matter ROIs. The SUV (that is, the tissue activity of MET per body weight) was calculated over the same tumor ROI as follows: SUV = (pixel count/pixel volume)/(injected radioisotope activity/body weight) ϫ calibration factor. During
201
Tl-SPECT studies we used a triple-head gamma camera (GCA9300A/HG; Toshiba, Tokyo, Japan). The SPECT images were acquired for 20 minutes, between 170 and 190 minutes after injection of 148 MBq of thallium-201. * Adeno = adenocarcinoma; BG = basal ganglia; cer = cerebellar; Dx = diagnosis; N = necrosis; ND = not done; occip = occipital; R = recurrence; RCC = renal cell carcinoma; SCC = squamous cell carcinoma; SMCC = small cell carcinoma; SRS = stereotactic radiosurgery; temp = temporal; ϩ = high uptake. Transverse, coronal, and sagittal scans were assessed qualitatively for areas of abnormal tracer uptake. Such areas were graded as either positive or negative for abnormality on the basis of visual analysis. In addition, an ROI was located over the area of maximal 201 Tl activity demonstrated on transaxial scans as well as the same size ROI over the contralateral portion. The
Tl index was defined as the ratio between the mean counts of radioisotope per pixel in the tumor ROI and the mean counts in the contralateral ROI. Interpretations of the scans were performed by two experienced nuclear medicine radiologists.
Histological Analysis
For histological studies, all sections were stained with hematoxylin and eosin. In Cases 10 and 11, sections were immunostained for GFAP and LCA.
Statistical Analysis
The T/N and SUV in both the pretreatment group and the recurrence group were compared using the Mann-Whitney U-test. Furthermore, T/N and SUV in the tumor recurrence and necrosis groups were compared using the Mann-Whitney U-test.
We chose arbitrary values of T/N and SUV and divided patients into two groups of above or below the value (high and low groups). We constructed a 2 ϫ 2 factorial table and calculated the probability value by using the Fisher exact test. We found that the lowest probability values corresponded with the borderline values of T/N and SUV for recurrence and necrosis.
Values are expressed as the means Ϯ standard deviation, unless noted otherwise. The level of significance was defined as a probability value less than 0.05. Tables 1 and 2 . The uptake of MET in the frontal lobe |in the 20 healthy volunteers showed no laterality, and the mean SUV was 1.36 Ϯ 0.29. In the 29 patients with tumor, the SUV in the contralateral (side without tumor) frontal lobe gray matter was 1.46 Ϯ 0.39. There was no significant difference between the healthy volunteers and patients harboring tumor with regard to the SUV in the frontal lobe.
Results

Clinical summaries and PET scanning results are shown in
The results of the 21 patients who underwent stereotactic radiosurgery are shown in Table 1 . Eleven patients (Cases 1-11) underwent biopsy or surgical resection after radiosurgery. Nine (Cases 1-9) of them were histologically proven to have tumor recurrence. In the patients in Cases 1 and 7, there were few tumor islands within the necrotic tissue. The patients in two cases (10 and 11) were histologically proven to have radiation necrosis with no viable tumor cells, and there was no sign of recurrence at the MR imaging and clinical follow up after more than 5 months post-PET scanning. In these two cases, samples stained negative for GFAP. Samples stained positive for LCA only in Case 10. Ten other patients (Cases 12-21) not subjected to histological analysis were determined to have radiation necrosis; these patients had stable neurological symptoms and no massive enlargement of the lesion on MR images more than 5 months after PET scanning (mean follow-up period 8. In the eight patients who underwent pretreatment MET-PET scanning (Cases 22-29) the T/N ranged from 1.74 to 3.58 (mean 2.24 Ϯ 0.64) and the SUV from 1.58 to 4.99 (mean 2.64 Ϯ 1.08). The degree of MET uptake was not dependent on the histological type of tumor.
There was a significant difference in the T/N (p = 0.027) between the pretreatment group (Cases 22-29) and the recurrence group (Cases 1-9), but none in the SUV. In contrast, there were more significant differences between the recurrence and necrosis groups in both the T/N (p = 0.0006; Fig. 1 ) and SUV (p = 0.0095).
In terms of visible accumulation of MET, results of MET-PET studies did not demonstrate high accumulation in two cases (1 and 7) in the recurrence group, but showed visible accumulation in two cases (10 and 19) in the necrosis group.
The lowest probability value was 0.0003, which related to the borderline T/N value of 1.42 in comparing the recurrence and necrosis groups (Table 3) . For SUV, the lowest probability value was 0.03 and the borderline SUV was 2.03 (Table 3 ). The sensitivity of both the T/N and SUV was found to be 77.8%, and the specificity of T/N and SUV was 100 and 75%, respectively. Tl-SPECT scanning results demonstrated visible accumulation in lesions and there was no significant difference between recurrence and necrosis groups.
Illustrative Cases
Case 1
This 70-year-old woman had been treated for metastatic tumor around the left basal ganglion (adenocarcinoma originating in the lung) by using GKS. Thirty-seven months after that treatment, follow-up MR images revealed an enlarging enhanced lesion (Fig. 2 left) . A 201 Tl-SPECT scanning demonstrated this lesion to be a high-uptake area. An MET-PET study revealed slight visible accumulation and a somewhat elevated T/N of 1.29 (Fig. 2 center) . From PET images we were unable to distinguish necrosis from recurrence, and the tumor was removed. After resection, histological analysis revealed a small tumorous lesion within the necrosis (Fig. 3) . This case was classified as a tumor recurrence.
Case 2
This 67-year-old woman had been treated for a left parietal metastatic tumor (adenocarcinoma originating in the lung) by using GKS. By 12.5 months after treatment, follow-up MR images revealed an enlarging enhanced lesion (Fig. 4 left) . Results of Fig. 4 right), and MET-PET studies revealed an increased uptake area and a high T/N (1.95; Fig. 4 center) . Based on SPECT scanning we could not distinguish necrosis from recurrence. Positron emission tomography results indicated that the lesion was a tumor recurrence, and the tumor was removed. Histological analysis showed viable tumor cells (Fig. 5) . This case was classified as tumor recurrence.
Case 10
This 66-year-old woman had been treated for a right frontal lobe metastatic tumor (adenocarcinoma originating in the lung) by using GKS. Sixteen months after treatment, follow-up MR images revealed an enlarging enhanced lesion (Fig. 6 left) , and her left motor weakness was worsening. A
201
Tl-SPECT scan demonstrated this lesion as a high-uptake area (Fig. 6 center) , and MET-PET studies confirmed increased uptake and a T/N of 1.41 (Fig. 6  right) . According to PET findings, the lesion was a tumor recurrence and thus it was removed. Histological analysis showed necrosis with vascular proliferation and no viable tumor cells (Fig. 7 left) . Staining with LCA showed positive findings (Fig. 7 right) . This suggests a visually false-positive case. This patient had no recurrence at follow-up MR imaging more than 5 months after PET scanning.
Case 12
This 65-year-old man noticed right hemiparesis during treatment for lung cancer (adenocarcinoma), and a left parietal metastatic tumor was observed. He was treated with
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Positron emission tomography studies after radiosurgery gamma knife radiation. Thirteen months after the radiation treatment, follow-up MR images revealed an enlarging enhanced lesion (Fig. 8 left) . A 201 Tl-SPECT scan demonstrated this lesion to be a high-uptake area ( 201 Tl index 5.2; Fig.  8 right) ; however, MET-PET studies revealed the same area as having decreased uptake and a low T/N ratio (0.98; Fig.  8 center) . Results of PET scanning indicated that the lesion was radiation necrosis. After 16 months of follow up, MR images revealed no extensive enhanced lesions and neurological findings were improved. This case was defined as radiation necrosis.
Discussion
Postradiation reactions in the central nervous system are well described in conventional radiotherapy literature; they can be classified as acute, early-delayed, and late-delayed reactions. Following radiosurgery, acute reactions occur in the same manner as those described following conventional radiotherapy. 24 These reactions include a transient swelling phenomenon caused by vasogenic edema that occurs 12 to 48 hours after therapy; this is fully reversible and not associated with long-term neurological damage. Early-delayed reactions occur from a few weeks to several months later than the subacute reactions following conventional fractionated radiotherapy or radiosurgery. This is probably due to temporary demyelination and vascular damage and may prove fully or partially reversible, or it may progress to permanent sequelae. Tumor swelling sometimes occurs in the early-delayed phase and is associated with edema in the surrounding normal brain. Tumor shrinkage occurs later, with subsidence of the surrounding edema. Similarly, contrast enhancement at this time, particularly in the tumor perimeter, reflects a host reactive response and not tumor activity. 19 Sometimes, it is not easy to distinguish this phenomenon and tumor recurrence. Persistent clinical neurological signs and MR imaging changes (best demonstrated on T 2 -weighted sequences) beyond 2 years indicate late damage or reaction. In the first stages, it is difficult to determine whether this response is tumor recurrence or radiation necrosis based on MR imaging, computerized tomography scanning, and other clinical studies.
24 Late-delayed reactions that typically appear from several months to many years posttreatment are irreversible and frequently progressive. Regardless, the development of reactions is uncommon, because stereotactic radiosurgery involves the use of high doses of radiation administered in one or two fractions to very limited volumes of brain tissue. 16 Positron emission tomography with FDG has been widely used in the evaluation of various tumors. Note that FDG-PET scanning displays increased glucose utilization by tumor tissue, which correlates with the degree of malignancy. 6 The clinical usefulness of this procedure in evaluating brain tumors has been generally accepted. In several reports authors state that FDG-PET scanning is a useful technique for examining either tumor recurrence or radiation necrosis. 7, 22, 23, 27 The FDG-PET studies demonstrate FDG hypometabolism in the area of radiation injury; however, it occasionally reveals hypometabolism in several glioma cases, including recurrent low-grade glioma. Although FDG-PET scanning is generally an excellent procedure for the differentiation of recurrent and residual tumor from radiation in-
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Positron emission tomography studies after radiosurgery jury, a differential diagnosis is difficult in some cases of recurrent brain tumor with FDG hypometabolism.
In contrast FDG, background uptake of amino acids in normal brain tissue is low, providing good contrast with tumor uptake. Most amino acid studies have been performed on brain tumors, usually with MET-PET scanning. Note that MET-PET scanning has been reported to be a useful technique in differentiating tumorous from nontumorous tissue, 15, 21, 22 detecting recurrent or residual tumors, distinguishing tumors from treatment-induced lesions, and correlating with the tumor's histological grade in glioma. 4 The MET-PET images can demonstrate the existence of tumorous cells, even in a small tumor, with the lesion being characterized by a marked uptake of MET; however, an increased uptake of MET has occasionally occurred in brain hematoma and in necrotic areas caused by radiation therapy performed to treat brain tumors. 5, 20 Ogawa, et al., 22 reported that the combined use of MET-and FDG-PET scanning can improve the accuracy in diagnosis of recurrent brain tumor and radiation injury. They showed that lesions characterized by hypometabolism of FDG and a high uptake of MET were recurrent tumors, and that lesions with hypometabolism of FDG and the same degree of MET uptake as that in contralateral cortical tissue were indicative of radiation injury. Nonetheless, it is actually difficult to obtain both FDG-and MET-PET images during the same period. On the other hand, Sonoda, et al., 26 reported that the ratio of tumor tissue to contralateral gray matter on MET-PET scans of recurrent glioma was significantly higher than that of radiation necrosis.
In our study, first, there was no significant difference between healthy and tumor groups in MET uptake (SUV) in the frontal lobe cortex (nonlesion side). This may indicate that metabolism of contralateral cortex is not affected by tumor invasion and radiosurgery. If the SUV of cortex on the nonlesional side is changeable, the T/N value may not make sense. Second, the significant difference in the T/N ratio between the pretreatment group and the recurrence group may suggest that MET uptake into recurrent tumor region is lower than that in the primary region, because of a recurrent tumor growing in a radiation-injured region. Finally, our results demonstrated that there were significant differences between recurrence and necrosis groups in T/N ratio and SUV. From these results, we can assert that MET-PET scanning is useful in differentiating metastatic brain tumor from radiation necrosis.
Based on MET-PET scanning results, we thought that two cases (1 and 7) were visually false negative, and another two (10 and 19) were visually false positive. It may be difficult to distinguish high or low uptake of MET, however, because visual evaluation is subjectively analyzed. On the other hand, the T/N ratio or SUV is objectively analyzed. We were able to estimate the borderline T/N ratio and SUV value between recurrence and necrosis groups by constructing a 2 ϫ 2 cross table and calculating the probability value by using the Fisher exact test. We found that the lowest probability value corresponded to a borderline T/N ratio of 1.42 and an SUV of 2.03. Table 3 shows two false-negative and no false-positive cases with regard to T/N, and two false-negative and three false-positive cases with regard to SUV. We believe that T/N ratio is superior to SUV as useful objective analysis. Given the high specificity of MET-PET scanning, if PET studies display high uptake (Ͼ 1.42 T/N) of MET in postradiation reactions in some cases, we may be able to perform a second stereotactic radiosurgery and consider the lesion as a tumor recurrence without surgical procedures.
The mechanism of the accumulation of MET remains unclear. The causes for its accumulation are thought to be increased protein synthesis by proliferative cells, 13 active carrier-mediated transport across the cell membrane, 4,10 disruption of the BBB, and high vascular density. On the basis of their results in an experimental study, Kubota, et al., 13 have reported that MET-PET studies were used to differentiate inflammation from tumor. On the other hand, Ishii, et al., 9 have speculated that the mechanism of MET uptake in brain abscess was due to increased metabolism and active amino acid transport due to the increased density of inflammatory cells as well as the disruption of the BBB arising from the discrepancy between the area of MET uptake and the Gd-enhanced lesion as revealed on MR images. Disruption of the BBB may not be necessary for increased MET uptake, especially given that high uptake of MET has been observed in low-grade glioma in which the BBB is intact. 6 In the late phase of radiation injury, vascular changes are well characterized. There is proliferation of endothelial cells and fibroblasts, as well as a perivascular inflammatory response characterized by the presence of lymphocytes, plasma cells, and macrophages. Inflammation occurs during the latent period up to the onset of late radiation-induced injury.
14 Furthermore, the radiation-induced astrocytic and microglial responses that follow brain radiation are indicative of reactive gliosis.
3, 28 Iwai, et al., 11 reported on a case with the accumulation of MET in radiation necrosis and suggested that the mechanism of uptake was reactive gliosis. We immunostained brain sections for GFAP as the marker of reactive gliosis, and LCA as the marker of inflammation (reacting macrophages and histiocytes) in two cases of necrosis (10 and 11) . In the patient with falsepositive results (Case 10), we detected many LCA-positive cells in the necrotic lesion, but no positive finding of GFAP in those lesions. The accumulation of MET in tissue with radiation injury is certainly thought to be related to disruption of the BBB and vascular proliferation. Given our findings, however, we think that the cause can be attributed to not only the disrupted BBB and vascularity, but also an inflammatory response. On the other hand, we observed viable tumor cells forming a small tumor island in necrotic tissue in two false-negative cases (1 and 7). We surmise that MET-PET studies did not show high accumulation because of the low density of tumor cells.
Note that 201 Tl-SPECT scanning is reported to be as effective as PET scanning in distinguishing radiation necrosis from brain tumor recurrence.
12, 18 Kline, et al., 12 showed that its sensitivity and specificity in cases in which gamma knife therapy was used were 92 and 67%, respectively. In fact, increased 201 Tl uptake has been observed in radiation necrosis and inflammatory infectious processes. 11 The use of thallium-201 in brain SPECT studies has been shown to be a sensitive, but relatively nonspecific, imaging modality in the evaluation of brain tumors. Nonneoplastic lesions with BBB disruption, including radiation necrosis, postsurgical inflammatory changes, 2, 17 hematomas, infarcts, and abscesses can also show increased 201 Tl uptake. 1 Sonoda, et al., 26 reported that there was no significant difference between radiation necrosis and tumor recurrence in 201 Tl-SPECT index. Schwartz, et al., 25 however, reported that dual-isotope ( Tl uptake, HMPAO uptake differentiated between cases with active tumor and those without; increased perfusion showed local recurrence, and decreased perfusion showed no recurrence. In our study, 201 Tl-SPECT scanning tended to demonstrate both radiation necrosis and tumor recurrence as lesions with increased accumulation.
Conclusions
We demonstrated that there were significant differences between the recurrence and necrosis groups on MET-PET scanning. Furthermore, the sensitivity and specificity were 77.8 and 100%, respectively, when the borderline T/N ratio was 1.42. Results of MET-PET studies matched the clinical diagnoses and is useful in differentiating metastatic brain tumor from radiation necrosis. In this study we presented important information for creating strategies to treat postradiation reactions.
